ImmunityBio Inc [NASDAQ: IBRX] closed the trading session at $7.35. The stocks have a year to date performance of 46.41 percent and weekly performance of 39.47 percent. The stock has been moved at 365.19 percent over the last six months. The stock has performed 34.62
ImmunityBio Inc [NASDAQ: IBRX] gained 11.13% on the last trading session, reaching $5.49 price per share at the time. If compared to the average trading volume of 4.22M shares, IBRX reached a trading volume of 30606873 in the most recent trading day, which is why
ImmunityBio Inc [NASDAQ: IBRX] gained 6.50% on the last trading session, reaching $5.24 price per share at the time. If compared to the average trading volume of 4.15M shares, IBRX reached a trading volume of 4411513 in the most recent trading day, which is why
ImmunityBio Inc [NASDAQ: IBRX] plunged by -$0.2 during the normal trading session on while it closed the day at $5.96. The company report on March 6, 2024 at 9:00 AM that NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral
ImmunityBio Inc [NASDAQ: IBRX] surged by $0.44 during the normal trading session on while it closed the day at $5.71. The company report on March 6, 2024 at 9:00 AM that NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral
ImmunityBio Inc [NASDAQ: IBRX] closed the trading session at $5.46. The company report on March 6, 2024 at 9:00 AM that NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy. ImmunityBio (NASDAQ: IBRX), a
ImmunityBio Inc [NASDAQ: IBRX] closed the trading session at $5.99. The company report on March 6, 2024 at 9:00 AM that NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy. ImmunityBio (NASDAQ: IBRX), a
ImmunityBio Inc [NASDAQ: IBRX] traded at a high on Wednesday, posting a 5.39 gain after which it closed the day’ session at $5.08. The company report on March 6, 2024 at 9:00 AM that NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to
ImmunityBio Inc [NASDAQ: IBRX] gained 19.71% or 0.69 points to close at $4.19 with a heavy trading volume of 10408121 shares. The company report on February 21, 2024 at 9:00 AM that ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in
ImmunityBio Inc [NASDAQ: IBRX] price surged by 11.97 percent to reach at $0.56. The company report on February 21, 2024 at 9:00 AM that ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized
© 2024, Powered by Smart TechOne
